Halpern Financial, Inc. 2seventy Bio, Inc. Transaction History
Halpern Financial, Inc.
- $389 Billion
- Q3 2024
A detailed history of Halpern Financial, Inc. transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Halpern Financial, Inc. holds 100 shares of TSVT stock, worth $244. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$244
Previous $385,000
24.94%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TSVT
# of Institutions
127Shares Held
45.6MCall Options Held
122KPut Options Held
19.8K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$14.5 Million2.31% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$10.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$9.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$8.93 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.89MShares$7.06 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $92.4M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...